AgingResearch.NewsJoin free

Frequency

Papers on frequency

11,764 papers406 new in 30 days

Monday, October 26

ESC Congress 2026 Abstract

Low-dose dapagliflozin linked to better heart failure outcomes

In a 96-week trial subanalysis, dapagliflozin 5 mg ranked better in 19.34% of patient-pair comparisons, versus 5.04% for control.In a 96-week trial subanalysis, dapagliflozin 5 mg ranked better in 19.34% of patient-pair comparisons, versus 5.04% for control.

Heart cutaways beside small patient groups contrast a thick-walled dark blue-green heart with a thinner-walled gray heart.
Randomized trialDapagliflozin
Paper
ESC Congress 2026 Abstract

Some blood-cell mutations linked to higher dementia risk

Mutations in two genes were linked to dementia, with adjusted hazard ratios of 1.14 and 1.29—relative measures of risk over time.Mutations in two genes were linked to dementia, with adjusted hazard ratios of 1.14 and 1.29—relative measures of risk over time.

Blood cells cluster beside a brain section with wider gaps, while fewer pale cells sit near a gray brain section with fuller tissue.
Cohort · 494,866 peopleIncident dementia
Paper
ESC Congress 2026 Abstract

Colchicine alters protein networks in a coronary disease trial

A randomized crossover trial analyzed 48 people with stable coronary artery disease and blood cell groups sharing genetic changes; colchicine altered inflammatory protein…A randomized crossover trial analyzed 48 people with stable coronary artery disease and blood cell groups sharing genetic changes; colchicine altered inflammatory protein networks.

A large white blood cell sits among densely clustered gray cells and proteins below and more widely scattered blue-green cells and proteins above.
Randomized trial · 48 peopleColchicine
Paper

Sunday, October 25

EClinicalMedicine

Elinzanetant’s safety profile appeared favorable in women

Over 12 weeks, new or worsening health problems occurred in 50.8% of women taking elinzanetant and 43.2% taking placebo.Over 12 weeks, new or worsening health problems occurred in 50.8% of women taking elinzanetant and 43.2% taking placebo.

Study design. aFor SWITCH-1, elinzanetant 40 mg, 80 mg, and 160 mg were excluded from the pooled safety analysis.
Meta-analysis · 1,519 peopleInterventions
Paper
Environmental Research, Health

Pollution links to hospital admissions varied with wildfire smoke

Relative risks of cardiovascular hospitalization were 1.09 without smoke waves versus 1.04 with them, comparing two-year particle pollution averages of 9 versus 5…Relative risks of cardiovascular hospitalization were 1.09 without smoke waves versus 1.04 with them, comparing two-year particle pollution averages of 9 versus 5 micrograms per cubic meter.

A large heart sits among airborne particles and people holding smaller hearts, with more black hearts in the group without an overhead smoke curl.
Cohort · 65,200,000 peoplePopulations
Paper
Journal of the American Society of Nephrology

Empagliflozin was well tolerated in a kidney disease trial

In both groups, 96% tolerated the full dose; height-adjusted kidney volume grew 10.5% a year with empagliflozin versus 5.1% with placebo.In both groups, 96% tolerated the full dose; height-adjusted kidney volume grew 10.5% a year with empagliflozin versus 5.1% with placebo.

Kidney cutaways show a large dark blue-green kidney crowded with large cysts beside a smaller gray kidney with fewer, smaller cysts.
Randomized trial · 50 peopleEmpagliflozin
Paper

Saturday, October 24